Skip to main content
    D

    Dynavax Technologies Corporation (DVAX)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $15.50
    +0.00 (+0.00%)

    Last updated: Feb 11, 2026 at 4:00 PM ET

    Dynavax Technologies Corporation (DVAX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2025. Financial statements from company filings, amounts in US dollars.

    Dynavax Technologies reported revenue of $277.25M for the fiscal year ended Dec 31, 2024, up 19.4% from the year before. That year, net income was $27.31M with a net margin of 9.9%, operating cash flow was $66.51M and free cash flow was $60.16M. The quarter ended Sep 30, 2025 had revenue of $94.88M and net income of $26.93M.

    Revenue and Margins

    The operating margin was -1.5% in the fiscal year ended Dec 2024. Over the 9 years to Dec 2024, revenue grew from $4.05M, a compound annual rate of 59.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$277.25M+19.4%82.2%-1.5%9.9%
    Dec 2023$232.28M-67.9%78.4%-15.9%-2.8%
    Dec 2022$722.68M+64.5%63.7%39.2%40.6%
    Dec 2021$439.44M+844.0%60.5%30.6%17.5%
    Dec 2020$46.55M+32.2%75.5%-146.9%-161.6%
    Dec 2019$35.22M+329.6%71.1%-382.9%-433.3%
    Dec 2018$8.20M+2407.0%-33.4%-1870.2%-1938.3%
    Dec 2017$327.00K-97.0%100.0%-29359.3%-29099.1%
    Dec 2016$11.04M+172.7%100.0%-1002.5%-1018.2%
    Dec 2015$4.05MN/A100.0%-2594.4%-2636.9%
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, net income turned positive after a loss the year before. In the quarter ended Sep 2025, net income rose 53.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$277.25M$232.28M$722.68M$439.44M$46.55M$35.22M$8.20M$327.00K$11.04M$4.05M
    Cost of revenue$49.45M$50.17M$262.15M$173.57M$11.41M$10.17M$10.93M$0$0$0
    Gross profit$227.80M$182.12M$460.53M$265.87M$35.14M$25.05M-$2.74M$327.00K$11.04M$4.05M
    Research and development$61.55M$54.89M$46.60M$32.23M$28.61M$62.33M$74.95M$64.99M$84.49M$86.94M
    Operating income-$4.12M-$37.03M$283.52M$134.49M-$68.37M-$134.84M-$153.32M-$96.00M-$110.71M-$105.07M
    Net income$27.31M-$6.39M$293.16M$76.71M-$75.24M-$152.60M-$158.90M-$95.15M-$112.44M-$106.79M
    EBITDAN/AN/A$287.81MN/A-$55.27M-$121.54M-$140.40M-$91.76M-$108.27M-$103.05M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$94.88M$95.44M$68.16M$72.03M$80.63M$73.80M$50.79M$55.60M$69.51M$60.25M$46.92M$184.49M
    Gross profit$80.47M$81.41M$54.40M$58.62M$67.55M$61.81M$39.82M$46.91M$56.28M$46.71M$32.21M$107.00M
    Operating income$21.27M$14.43M-$23.63M-$1.63M$10.08M$5.20M-$17.77M-$8.49M$5.12M-$3.40M-$30.25M$63.13M
    Net income$26.93M$18.72M-$96.10M$7.05M$17.59M$11.39M-$8.72M$219.00K$14.29M$3.43M-$24.33M$67.73M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, total debt of $223.85M exceeded cash and equivalents by $127.97M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$986.26M$997.10M$985.85M$1.04B$353.27M$279.07M$210.88M$218.78M$109.68M$216.63M
    Current assets$848.94M$859.12M$916.99M$972.52M$290.01M$208.65M$174.36M$198.02M$89.60M$199.95M
    Cash and equivalents$95.88M$150.28M$202.00M$436.19M$32.07M$39.88M$49.35M$26.58M$24.29M$44.81M
    Total liabilities$389.46M$375.02M$404.84M$816.87M$294.58M$270.78M$147.82M$19.24M$20.48M$29.55M
    Short-term debt$0$4.50M$3.63M$2.58M$3.25M$3.04MN/AN/AN/AN/A
    Long-term debt$223.85M$222.70M$221.58M$220.49M$179.81M$178.60M$100.87M$0$0$0
    Shareholder equity$596.80M$622.07M$581.01M$222.37M$58.69M$8.29M$63.06M$199.55M$89.20M$187.08M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$946.51M$918.45M$945.93M$986.26M$1.06B$1.02B$986.57M$997.10M$972.93M$936.43M$969.92M$985.85M
    Total liabilities$412.37M$424.29M$414.99M$389.46M$380.56M$373.47M$368.08M$375.02M$368.02M$359.23M$406.19M$404.84M
    Cash and equivalents$160.25M$99.10M$51.72M$95.88M$119.33M$112.50M$132.03M$150.28M$154.51M$226.82M$174.35M$202.00M
    Shareholder equity$534.14M$494.16M$530.94M$596.80M$681.43M$642.85M$618.48M$622.07M$604.92M$577.21M$563.73M$581.01M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2024, free cash flow was 90.5% of operating cash flow. Share repurchases came to 166.2% of it.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow$66.51M$100.56M$62.72M$335.53M-$92.25M-$121.25M-$131.30M-$77.52M-$107.05M-$92.56M
    Capital expenditures$6.35M$4.10M$7.14M$9.48M$4.07M$22.40M$4.19M$669.00K$7.76M$6.97M
    Free cash flow$60.16M$96.46M$55.58M$326.05M-$96.32M-$143.65M-$135.49M-$78.19M-$114.81M-$99.53M
    Share repurchases$100.00M$0$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$18.04M-$153.93M-$316.00M$14.22M-$26.53M-$42.78M$55.47M-$108.70M$86.25M-$85.80M
    Financing cash flow-$102.02M$1.39M$19.52M$55.78M$109.50M$154.35M$99.07M$187.84M$531.00K$173.96M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow$33.83M$23.43M-$19.64M$53.01M$19.47M$10.71M-$16.68M$13.77M$31.13M$28.05M$27.62M$34.95M
    Capital expenditures$1.24M$1.45M$3.93M$3.48M$1.35M$779.00K$749.00K$1.72M$347.00K$751.00K$1.28M$1.59M
    Free cash flow$32.59M$21.98M-$23.57M$49.53M$18.12M$9.93M-$17.43M$12.04M$30.78M$27.30M$26.34M$33.36M
    Last 12 quarters

    Frequently Asked Questions About DVAX

    What is Dynavax Technologies' annual revenue?

    Dynavax Technologies reported revenue of $277.25M for the fiscal year ended Dec 31, 2024.

    How fast is Dynavax Technologies' revenue growing?

    Revenue was up 19.4% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -14.2%.

    Is Dynavax Technologies profitable?

    Yes. Dynavax Technologies reported net income of $27.31M for the fiscal year ended Dec 31, 2024, with a net margin of 9.9%.

    How much free cash flow does DVAX generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of $66.51M minus capital expenditures of $6.35M produced free cash flow of $60.16M.

    How much debt does Dynavax Technologies have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $223.85M, short-term debt of $0 and cash and equivalents of $95.88M.